Methylprednisolone Acetate
Brand Names: Medroloan Ii Suik, Depo-Medrol, Medroloan Suik, Medrol
Methodology & AI Transparency ⓘ
Methylprednisolone Acetate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: A.
- 2 Real-world patient consensus: Zero-PHI community consensus: 90% favorable across 4 logged regimens (Medroloan Ii Suik, Depo-Medrol).
- 3 Typical cash cost range: Public pharmacy ledger: $7.00 low cash benchmark vs. $34.50 chain retail average ($10.8023/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Methylprednisolone Acetate tolerability events: peripheral edema (3.4%), palpitations (2.4%), nausea (8.7%).
Ask our AI Specialists anything about Methylprednisolone Acetate
Methylprednisolone Acetate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic analogs are used primarily for their anti-inflammatory effects in disorders of many organ systems.
Pharmacokinetic profiling of Methylprednisolone Acetate demonstrates an elimination half-life of Mean elimination half-life of 10 to 22 hours across adult Methylprednisolone Acetate dosing with Complete (~100%) parenteral systemic delivery for Methylprednisolone Acetate (20 mg/mL Injection, Suspension) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of methylprednisolone acetate, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after methylprednisolone acetate administration.
Titration schedules for Methylprednisolone Acetate (20 mg/mL Injection, Suspension → 80 mg/mL Injection, Suspension → 40 mg/mL Injection, Suspension → 16mg Tablet → 32mg Tablet) require excluding contraindications depo-medrol is contraindicated in patients with known hypersensitivity to the product and its constituents.; intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.; depo-medrol is contraindicated for intrathecal administration.; real-world patient logs highlight nausea (8.7% of reports), headache (7.2% of reports), fatigue (5.4% of reports) alongside a 90.00% Worth-It consensus.
Electrolyte retention and renal perfusion changes are more likely when Methylprednisolone Acetate overlaps with RAAS blockade.
Reconcile eGFR-adjusted medications before escalating Methylprednisolone Acetate in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS DEPO-MEDROL is contraindicated in patients with known hypersensitivity to the product and its constituents.
- Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.
- DEPO-MEDROL is contraindicated for intrathecal administration.
Logged Side-Effect Incidence (4 Reports)
Methylprednisolone Acetate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Methylprednisolone Acetate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a Our results suggest that intravenous immunoglobulin could be a safe and efficacious therapeutic option for prompt treatment of steroid-resistant acute ON. Japanese journal of ophthalmology • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33469728 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term foot outcomes following differential abatement of inflammation and Bisphosphonate for active CN is associated with an increase in foot bone mineral content as compared to decrease with steroids or total contact cast but long-term outcomes of foot deformities, ulceration and amputation are... PloS one • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34748565 ↗ |
| New Insights on Intraoperative corticosteroid administration for resectable gastric cancer: a: What a 202-Participant Study Found Intraoperative CS administration mitigated postoperative CRP elevation but did not result in significantly improved survival in patients with cStage II-III gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • 2025-09-15 • Phase III Randomized Trial | N = 202 | 82/100 | PMID 40638018 ↗ |
| Can This Approach Help? Inside the Latest Research on Mini-dose methotrexate combined with methylprednisolone for the initial treatment Mini-dose MTX combined with corticosteroids can significantly improve the ORR in patients with aGVHD and is well tolerated, although it did not achieve the prespecified 20% improvement with the addition of MTX. BMC medicine • 2024-04-25 • Phase III Randomized Trial | N = 157 | 82/100 | PMID 38664766 ↗ |
| Can This Approach Help? Inside the Latest Research on Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, Side effects (AEs) frequencies were comparable between both groups, with the exception of fewer grade 4 AEs in the RUX/steroids group (26.3% vs. Signal transduction and targeted therapy • 2024-10-23 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39438467 ↗ |
Methylprednisolone Acetate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $10.8023/unit (~$324.07/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $7.00 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $8.05 / mo | View logs ↓ |
Methylprednisolone Acetate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Methylprednisolone Acetate RxNorm Concept ID | 1743779 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $10.8023 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $7.00 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Methylprednisolone Acetate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Methylprednisolone Acetate integrating DailyMed SPL (2025-11-06), CMS NADAC ($10.8023/unit), and 4 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Methylprednisolone Acetate community threads and patient logs by age, biological sex, dosage, and treatment duration.